A Mab A Case Study In Bioprocess Development !new! Jun 2026

We conducted an excipient screening study . By introducing a specific ratio of arginine and sucrose, we successfully shielded the protein-protein interactions that caused viscosity. This stabilized the molecule without compromising the shelf life.

| Challenge | Finding | Solution | |-----------|---------|----------| | (pilot scale) | Shear from peristaltic pump in harvest line | Switch to low-shear diaphragm pump | | Protein A carryover | Leakage ~150 ppm | Add intermediate wash (1 M NaCl + 0.1% Triton) → reduced to 25 ppm | | Aggregate formation during viral inactivation | pH 3.5 for 60 min → 2% aggregates | Reduce hold time to 45 min, add 0.1% PS80 | | UF/DF flux drop | Concentration polarization | Increase crossflow, use 30 kDa Hydrosart membrane |

The process begins by establishing the "end goal" before any manufacturing starts. International Society for Pharmaceutical Engineering (ISPE) Target Product Profile (TPP): A Mab A Case Study In Bioprocess Development

Operated in bind-elute mode. Effectively separated charge variants and removed HMW aggregates.

The selected cell line, CHO-A Mab, was then adapted to grow in a serum-free medium, which is essential for large-scale production. We conducted an excipient screening study

A chemically defined, serum-free medium was used. Design of Experiments (DoE) screened various concentrations of amino acids, vitamins, and trace elements.

Today, we are diving into a hypothetical but realistic case study of a monoclonal antibody targeting a specific inflammatory marker. We will explore the critical decision points that process engineers face when scaling a biologic from the bench to the bioreactor. The selected cell line, CHO-A Mab, was then

, protecting downstream chromatography columns from fouling. Capture Step: Protein A Chromatography

Low pH hold (pH 3.6 for 60 minutes) was used. But with A Mab’s sensitivity, they optimized to pH 3.7 for exactly 30 minutes – no longer, no shorter. Validation showed >4 log reduction of model virus (xMuLV).

In this article, we dissect a hypothetical but realistic (Monoclonal Antibody A) as a detailed case study in bioprocess development . We will follow A Mab from the cloning stage through upstream processing, downstream purification, formulation, and finally to scale-up and regulatory filing. This case study illustrates the critical decisions, pitfalls, and innovations that define modern bioprocess engineering.

The final scale-up from pilot (200L) to commercial (2,000L) was smooth, but transferring to an external CMO at 10,000L revealed surprises: